anti-BMCA CAR NK-cell therapy (Hangzhou Cheetah Cell Therapeutics/Zhejiang University)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-BMCA CAR NK-cell therapy (Hangzhou Cheetah Cell Therapeutics/Zhejiang University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 modulatorsImmunostimulantsNatural killer cells stimulants
TargetsTumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesZhejiang University
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Cheetah Cell Therapeutics Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A